Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingLivmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“EU”) and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (“PFIC”) in the U.S., Canada and Japan and for the treatment of PFIC in the EU.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q2 2026 · $176.2MThe company’s own SEC segment disclosure.
- Livmarli$128.7M73%
- Bile Acid Medicines$47.5M27%
Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $176M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with net loss of $67M. For the full year FY2025, revenue was $521M (+55% year on year) and net income −$23M. Its largest product in Q2 2026 was Livmarli at $129M, 73% of the disclosed total, well ahead of Bile Acid Medicines at 27%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.